Insights

More Articles Back to Article

France approves national reimbursement deal for CF drug Orkambi

The French authorities have approved a national reimbursement deal for Vertex Pharmaceuticals' drug Orkambi, or lumacaftor/ivacaftor, to treat patients with cystic fibrosis who have two copies of the F508del mutation in their CTFR gene. France has among the largest population of patients with CF after the UK and the US. PMLive (UK) (11/21)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!